Advanced Life Sciences
Advanced Life Sciences
  • Home
  • About
    • Management Team
    • Board of Directors
    • Scientific Advisors
    • Careers
  • Products
    • Phase 3 ORCA-3 Trial
    • Phase 3 ORCA-2 Trial
    • Phase 2 ORCA-1 Trial
    • Phase 2 ORCA-V1 Trial
    • Expanded Access Policy
    • Resources
  • Investors
  • News
  • Contact
  • Smoking Cessation
  •    Phase 3 ORCA-3 Trial
  •    Phase 3 ORCA-2 Trial
  •    Phase 2 ORCA-1 Trial
  • Vaping Cessation
  •    Phase 2 ORCA-V1 Trial
  • Expanded Access Policy
  • Resources
  • Smoking Cessation
  •    Phase 3 ORCA-3 Trial
  •    Phase 3 ORCA-2 Trial
  •    Phase 2 ORCA-1 Trial
  • Vaping Cessation
  •    Phase 2 ORCA-V1 Trial
  • Expanded Access Policy
  • Resources

ATS 2026 Annual Meeting

Comparative effectiveness of cytisinicline and varenicline for smoking cessation: A matching-adjusted indirect comparison (MAIC)

Cytisinicline for cigarette smoking and e-cigarette vaping cessation: Long-term safety data from the ORCA-OL clinical trial

SRNT 2026

Efficacy of Cytisinicline for Smoking Cessation in Adults with and without Multiple Prior Quit Attempts or Prior Pharmacotherapy Use: Pooled Analysis of Two Phase 3 Trials

Cytisinicline in Adult Smokers: Post-Trial Survey From ORCA-OL

 

  • US Headquarters
  • 22722 29th Dr SE,
    Suite 100
  • Bothell, WA 98021
  • Phone: (425) 686-1500
  • Vancouver Office
  • 1040 W Georgia Street,
    Suite 1030
  • Vancouver, BC V6E 4H1

About

  • About
  • Management Team
  • Board of Directors
  • Scientific Advisors
  • Careers

For Investors

  • Investors
  • News
  • Corporate Governance
  • Financial Information
  • SEC Filings

Recent News

May 19, 2026
Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment
More News

© Copyright 2026 | Achieve Life Sciences, Inc. All Rights Reserved

  • Privacy Policy
  • Disclaimer
  • Contact
  • References
  • twitter
  • linkedin